Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13376 - 13400 of 13806 in total
2,2':6',2''-terpyridine Platinum(Ii) is a solid. Known drug targets of 2,2':6',2''-Terpyridine Platinum(Ii) include truncated transposase and autolysin.
Experimental
Matched Name: … 2,2':6',2''-Terpyridine Platinum(Ii) …
Matched Iupac: … platinum(2+) 6-(pyridin-2-yl)-2,2'-bipyridine chloride …
Matched Description: … 2,2':6',2''-terpyridine Platinum(Ii) is a solid. ... Known drug targets of 2,2':6',2''-Terpyridine Platinum(Ii) include truncated transposase and autolysin …
Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
Investigational
Matched Description: … Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials …
Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
Investigational
Matched Description: … Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of …
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Matched Iupac: … N,N-dimethyl-5-({2-methyl-6-[(5-methylpyrazin-2-yl)carbamoyl]-1-benzofuran-4-yl}oxy)pyrimidine-2-carboxamide …
Matched Description: … PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Heterocyclic Compounds, 2-Ring …
BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).
Investigational
Matched Iupac: … N-ethyl-2-fluoro-N-methyl-4-[(5S)-5-{1-methyl-1-[(1,3,4-thiadiazol-2-yl)carbamoyl]ethyl}-5H-chromeno[ ... 2,3-b]pyridin-2-yl]benzamide …
Matched Description: … BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Investigational
Matched Iupac: … 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide …
Matched Description: … 06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Heterocyclic Compounds, 2-Ring …
RO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Matched Iupac: … (6),4,7,10,12-pentaen-9-yl]-N-[3-(4-methylpiperazin-1-yl)propyl]acetamide ... 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2
Matched Description: … RO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.
Investigational
Matched Description: … Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified …
Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Investigational
Matched Description: … Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and …
OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.[A254561, L47351]
Investigational
Matched Description: … OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute …
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
Matched Description: … CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. …
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
Matched Description: … MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. …
Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)).
Investigational
Matched Description: … Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety …
Ecnoglutide is under investigation in clinical trial NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity).
Investigational
Matched Description: … Ecnoglutide is under investigation in clinical trial NCT05813795 (A Phase 3 Study to Evaluate the Efficacy …
MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
Investigational
Matched Description: … MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. …
The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.
Investigational
Matched Description: … The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable …
Pumice is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Pumice is a plant/plant extract used in some OTC (over-the-counter) products. …
LY-2881835 is under investigation in clinical trial NCT01358981 (A Study of LY2881835 in Healthy People and People With Diabetes).
Investigational
Matched Iupac: … (3S)-3-(4-{[4-({spiro[indene-1,4'-piperidin]-1'-yl}methyl)phenyl]methoxy}phenyl)hex-4-ynoic acid …
Matched Description: … LY-2881835 is under investigation in clinical trial NCT01358981 (A Study of LY2881835 in Healthy People …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).
Investigational
Matched Iupac: … 2-{4-[(4-{[1-cyclopropyl-3-(oxan-4-yl)-1H-pyrazol-4-yl]oxy}pyridin-2-yl)amino]pyridin-2-yl}propan-2-ol …
Matched Description: … LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab …
Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).
Investigational
Matched Description: … Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With …
SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for the treatment of hemophilia.
Investigational
Matched Description: … SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for …
PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated Thr231-Pro232 motif in tau.
Investigational
Matched Description: … PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated …
TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.
Investigational
Matched Description: … TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1 …
A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarboxylic acid. A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure.
Experimental
Matched Iupac: … (1s,4s)-4-{1-[(2S)-2-carboxy-2-[(2-methoxyethoxy)methyl]ethyl]cyclopentaneamido}cyclohexane-1-carboxylic …
Matched Description: … acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarboxylic ... A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro ... A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic …
"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the Erythroxylum genus, though this name is also applied to infusions of plants belonging to other genera. The infusion is thought to carry stimulant and aphrodisiac effects, and catuaba made specifically with Trichilia...
Experimental
Matched Description: … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _ …
Displaying drugs 13376 - 13400 of 13806 in total